| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | kl13A |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是假设性示例，供参考(实际文献需根据具体研究检索)：
1. **"Functional characterization of recombinant KL13A protein in epithelial cell signaling"**
- 作者：Zhang L, et al.
- 摘要：研究通过体外表达KL13A重组蛋白，揭示其在调控上皮细胞增殖和凋亡中的作用，证实其通过MAPK通路影响细胞功能。
2. **"Structural analysis and immunogenicity of KL13A recombinant antigen in vaccine development"**
- 作者：Smith J, et al.
- 摘要：解析KL13A重组蛋白的晶体结构，评估其作为疫苗候选抗原的潜力，显示在小鼠模型中诱导特异性抗体反应。
3. **"KL13A recombinant protein as a biomarker for early-stage cancer detection"**
- 作者：Wang Y, et al.
- 摘要：开发基于KL13A重组蛋白的ELISA检测方法，验证其在血清中的表达水平与多种癌症早期诊断的相关性。
4. **"Production and purification of KL13A in E. coli: Optimization and functional validation"**
- 作者：Gupta R, et al.
- 摘要：优化大肠杆菌系统中KL13A重组蛋白的高效表达与纯化工艺，并验证其体外酶活性及稳定性。
---
**注意**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台检索关键词(如"KL13A recombinant")。若研究领域冷门或命名有误，建议核实蛋白名称或扩展检索策略。
**Background of KL13A Recombinant Protein**
KL13A is a recombinant protein engineered through genetic modification, designed to mimic or enhance specific biological functions of its native counterpart. While detailed information on KL13A remains limited in public databases, its nomenclature suggests affiliation with the KL (Kallikrein-related peptidase) protein family or a structurally similar group. Kallikrein-related proteins are serine proteases involved in diverse physiological processes, including tissue remodeling, inflammation, and cellular signaling. KL13A may share functional or structural homology with these enzymes, potentially targeting extracellular matrix components or regulating protease-activated pathways.
Recombinant KL13A is typically produced using expression systems such as *E. coli*, yeast, or mammalian cells, followed by purification via affinity chromatography to ensure high specificity and activity. Its development aims to address research or therapeutic needs, such as studying protease-mediated mechanisms, modulating immune responses, or exploring applications in regenerative medicine.
Emerging studies highlight recombinant KL proteins as promising tools in cancer research, wound healing, and autoimmune disease models. KL13A’s potential to interact with growth factors, cytokines, or cell surface receptors positions it as a candidate for drug discovery or biomarker development. However, further characterization of its substrate specificity, regulatory roles, and *in vivo* behavior is required to validate its utility.
In summary, KL13A represents a novel recombinant protein with hypothesized roles in proteolytic pathways and tissue homeostasis. Its engineered design enables scalable production for functional studies, though comprehensive mechanistic insights remain an active area of investigation.
×
